DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Teveten HCT (Eprosartan Mesylate / Hydrochlorothiazide) - Summary

 
 



USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, TEVETEN® HCT Tablets should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

 

TEVETEN HCT SUMMARY

TEVETEN® HCT 600/12.5 mg and TEVETEN® HCT 600/25 mg (eprosartan mesylate-hydrochlorothiazide) combine an angiotensin II receptor (AT1 subtype) antagonist and a diuretic, hydrochlorothiazide. TEVETEN® (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist.

TEVETEN® HCT is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).


See all Teveten HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Combination Therapy Improves Pulmonary Hypertension Outcomes
Source: Medscape Medical News Headlines [2016.05.20]
Combination therapy reduces the risk of clinical worsening in idiopathic and connective-tissue-associated pulmonary arterial hypertension better than monotherapy, according to a new meta-analysis.
Medscape Medical News

Hypertension in Pregnancy Ups Intellectual Disability, ASD Risk
Source: Medscape Psychiatry & Mental Health Headlines [2016.05.19]
Children born of mothers who have any form of hypertension during pregnancy are at elevated risk for intellectual disability and autism.
Medscape Medical News

American Society of Hypertension (ASH) 2016 Annual Scientific Meeting
Source: theheart.org | Medscape Cardiology Headlines [2016.05.17]
Read clinically focused news coverage of key developments from ASH 2016.
theheart.org on Medscape

Around-the-clock monitoring may unmask hypertension in African-Americans
Source: Hypertension News From Medical News Today [2016.05.17]
Ambulatory blood pressure monitoring, a device which measures blood pressure around-the-clock may help identify African Americans who have "masked" or undetected high blood pressure.

High Blood Pressure (Hypertension): Warning Signs, Risks, Medications
Source: MedicineNet Nosebleed Specialty [2016.05.13]
Title: High Blood Pressure (Hypertension): Warning Signs, Risks, Medications
Category: Slideshows
Created: 3/9/2011 12:10:00 PM
Last Editorial Review: 5/13/2016 12:00:00 AM

more news >>

Published Studies Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). [2010.06]
INTRODUCTION: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ) 12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients with grade 2 systolic hypertension who did not optimally respond to eprosartan or losartan monotherapy... CONCLUSION: In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly.

Safety and tolerability of eprosartan in combination with hydrochlorothiazide. [2002]
The ideal antihypertensive drug should be effective in reducing blood pressure, but have a low incidence of adverse effects... Therefore, the combination of eprosartan with hydrochlorothiazide can be effectively and safely used in patients not adequately responding to eprosartan monotherapy.

more studies >>

Clinical Trials Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension [Completed]
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers [Completed]
The purpose of this study is to find out how chemicals in the blood of patients with chronic kidney disease affect how medications are removed from the body. The patient will take one dose of three different drugs, one on each week, for a total of three single doses. The investigators want to find out if these three different medications are affected in different ways by the chemicals in the blood of patients with kidney disease.

The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans. [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan

reduces the activity of the sympathetic nervous system in healthy individuals - during

baseline conditions and after activation of the sympathetic nervous system.

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes [Completed]

The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential

hypertension - during baseline conditions and after activation of the sympathetic nervous

system.

more trials >>


Page last updated: 2016-05-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015